aTYR PHARMA INC Cash Flow Statement
ATYR|7 years of annual SEC 10-K data (FY2019-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 7 fiscal years. All figures from audited SEC 10-K filings.
aTYR PHARMA INC used $62M in operating cash flow and negative free cash flow of $62M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -6.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Income | -$74.1M | -$64.0M | -$33.8M | -$16.2M | -$23.6M | -$34.5M | -$48.2M |
| Depreciation & Amortization | $664.0K | $708.0K | $475.0K | $569.0K | $635.0K | $746.0K | $713.0K |
| Operating Cash Flow | -$62.0M | -$69.1M | -$33.1M | -$15.3M | -$20.0M | -$31.1M | -$42.4M |
| Capital Expenditures | $77.0K | $65.0K | $192.0K | $202.0K | $79.0K | $594.0K | $1.3M |
| Free Cash Flow | -$62.1M | -$69.2M | -$33.3M | -$15.5M | -$20.1M | -$31.7M | -$43.7M |
| FCF Margin | -32664.7% | -29440.0% | - | -148.3% | -4761.1% | -7501.7% | -10349.8% |